SCHEMBL29378252

SCHEMBL29378252

N#Cc1ccc(N2CCN(Cc3ccc(Cc4ccc5c6c(cccc46)C(=O)N5)cc3)CC2)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADRA1D P25100 3/20 0.52
ADRA1A P35348 3/20 0.52
ADRA1B P35368 3/20 0.52
CRBN Q96SW2 4/20 0.48
DDB1 Q16531 3/20 0.48
IKZF3 Q9UKT9 2/20 0.48
PARP1 P09874 8/20 0.47
TNK1 Q13470 6/20 0.47
TNK2 Q07912 3/20 0.47
CHRM4 P08173 2/20 0.41
DRD2 P14416 2/20 0.38
DRD4 P21917 1/20 0.38
DRD3 P35462 1/20 0.38
CHRM2 P08172 1/20 0.38
HTR1A P08908 1/20 0.37
GPR6 P46095 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22532669 1.00 ADRA1D (0.52) ADRA1DADRA1AADRA1BCRBNDDB1
SCHEMBL22533363 0.94 ADRA1D (0.49) ADRA1DADRA1AADRA1BCRBNDDB1
SCHEMBL22533066 0.90 ADRA1D (0.46) ADRA1DADRA1AADRA1BCRBNDDB1
SCHEMBL22533445 0.90 ADRA1D (0.45) ADRA1DADRA1AADRA1BCRBNDDB1
SCHEMBL22533091 0.89 ADRA1D (0.48) ADRA1DADRA1AADRA1BCRBNDDB1
SCHEMBL27454482 0.89 ADRA1D (0.47) ADRA1DADRA1AADRA1BCRBNDDB1
SCHEMBL27454480 0.89 ADRA1D (0.47) ADRA1DADRA1AADRA1BCRBNDDB1
SCHEMBL22533360 0.88 ADRA1D (0.43) ADRA1DADRA1AADRA1BCRBNDDB1
SCHEMBL22532983 0.88 DRD4 (0.40) ADRA1DADRA1AADRA1BCRBNDDB1
SCHEMBL22532696 0.86 ADRA1D (0.41) ADRA1DADRA1AADRA1BCRBNDDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4228624-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 Therapeutics, Inc. (US) 2023-08-23 EP disclosed
EP-4192450-A1 ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS C4 Therapeutics, Inc. (US) 2023-06-14 EP disclosed
WO-2022081927-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed
WO-2022032132-A1 ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS C4 THERAPEUTICS, INC. (US) 2022-02-10 WO disclosed